PRLD (Prelude Therapeutics) Beginning Cash Position: $38.49 Mil (As of Mar. 2026)


PRLD Prelude Therapeutics Inc PRLD
26 GF Score
Price $4.99
! 6 Warning Signs
View Full Analysis

What is Prelude Therapeutics Beginning Cash Position?

Prelude Therapeutics PRLD +1.63% 26 Beginning Cash Position is $38.49 Mil as of Mar. 2026. GuruFocus rates PRLD with a GF Score™ of 26/100. The stock has 6 warning signs investors should review.

Prelude Therapeutics's Beginning Cash Position for the quarter that ended in Mar. 2026 was $38.49 Mil.

Prelude Therapeutics's quarterly Beginning Cash Position increased from Sep. 2025 ($29.80 Mil) to Dec. 2025 ($50.77 Mil) but then declined from Dec. 2025 ($50.77 Mil) to Mar. 2026 ($38.49 Mil).

Prelude Therapeutics's annual Beginning Cash Position declined from Dec. 2023 ($34.65 Mil) to Dec. 2024 ($29.34 Mil) and declined from Dec. 2024 ($29.34 Mil) to Dec. 2025 ($16.52 Mil).

Prelude Therapeutics Beginning Cash Position Related Terms

Prelude Therapeutics Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Prelude Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prelude Therapeutics Beginning Cash Position Chart

Prelude Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial 218.31 35.87 34.65 29.34 16.52

Prelude Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.52 44.31 29.80 50.77 38.49
PRLD
26GF Score
Prelude Therapeutics Inc PRLD
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Prelude Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $38.49 Mil mean?
Prelude Therapeutics (PRLD) has a Beginning Cash Position of $38.49 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Prelude Therapeutics and its competitors.
Is Prelude Therapeutics' Beginning Cash Position too high?
Prelude Therapeutics' current Beginning Cash Position is $38.49 Mil. Overall, Prelude Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Prelude Therapeutics' Beginning Cash Position compare to DMAC and RCKT?
Prelude Therapeutics' Beginning Cash Position of $38.49 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Prelude Therapeutics and its competitors. Prelude Therapeutics's current Beginning Cash Position is $38.49 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prelude Therapeutics stock overvalued right now?
Prelude Therapeutics (PRLD) has a current Beginning Cash Position of $38.49 Mil. The current Beginning Cash Position is $38.49 Mil. Prelude Therapeutics' overall GF Score™ is 26/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Prelude Therapeutics (PRLD), the current Beginning Cash Position is $38.49 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Prelude Therapeutics Business Description

Address 175 Innovation Boulevard, Wilmington, DE, USA, 19805
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.
26GF Score

Get the complete analysis for PRLD

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.99
Price